Iron Deficiency Guidance Varies in Premenopausal Women - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Iron Deficiency Guidance Varies in Premenopausal Women

A Beyond the Guidelines discussion highlighted uncertainty around gastrointestinal evaluation and intravenous iron use in premenopausal women with iron deficiency.

  • By

  • Andrea Surnit

  • June 11, 2026

  • 5 min

Share

Objective:

To discuss the varying approaches to diagnosing and treating iron deficiency in premenopausal women, particularly in the context of a case study.

Approach:
    Key Findings:
    • Ferritin is the most useful noninvasive marker of iron deficiency, but lower diagnostic thresholds may miss patients needing treatment.
    • Traditional sex-specific hemoglobin thresholds may lead to underrecognition of iron deficiency in menstruating women.
    • There is disagreement on the necessity of gastrointestinal evaluation in asymptomatic premenopausal women with iron deficiency anemia.
    Interpretation:

    The discussion highlights varying expert opinions on gastrointestinal evaluation and iron replacement strategies in managing iron deficiency in premenopausal women.

    Limitations:
    • The article is based on a Grand Rounds discussion rather than original clinical trial data.
    • It does not provide new outcomes data.
    Conclusion:

    The article emphasizes the importance of considering various clinical factors in treating iron deficiency in premenopausal women.

    Sources:

Original Source(s)

Iron Deficiency Guidance Varies in Premenopausal Women

  • by Andrea Surnit

  • June 11, 2026

Related Content

Medical Oddities: Something Viral is Lurking in the Dust

Everyday things like yawns, tea, dust, and kimchi suddenly look medically important.

Measles Renews Focus on Vaccine Waivers

“And when one of these measles cases ends up in a low-immunization community, that's when the ember really has a chance to expand and become a wildfire.”

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.